Document:

EX-10.11

 Exhibit 10.11 

 
 

 
 Amprius Technologies, Inc. 

September 28, 2022 
 Constantin Ionel Stefan 

c/o Amprius Technologies, Inc. 
 1180 Page Avenue 

Fremont, California 94538 
 Re: Amended and Restated
Confirmatory Employment Letter 
 Dear Ionel: 

This amended and restated letter agreement (the “Agreement”) is entered into between Constantin Ionel Stefan
(“you”) and Amprius Technologies, Inc. (the “Company” or “we”). This Agreement is effective as of the date you sign it, as indicated below. The purpose of this Agreement is to confirm the current
terms and conditions of your employment and shall supersede any and all previous employment agreements signed by you. 
 1. Position.
Your position will continue to be Chief Technology Officer, and you will continue to report to the Company’s Chief Executive Officer or to such other person as the Company subsequently may determine. This is a full-time position. You will
perform the duties and have the responsibilities and authority customarily performed and held by an employee in your position or as otherwise may be assigned or delegated to you by the Company. While you render services to the Company, you will not
engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this Agreement, you reconfirm to the
Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 

2. Base Salary. Your current annual base salary is $250,000, which will be payable, less applicable withholdings and deductions, in
accordance with the Company’s normal payroll practices. Your annual base salary will be subject to review and adjustment based upon the Company’s normal performance review practices. 

3. Annual Bonus. You are eligible to earn an annual cash bonus with a target value of 30% of your annual base salary, based on
achieving performance objectives established by the Board or an authorized committee of the Board (such committee, a “Committee”) in its sole discretion and payable upon achievement of those objectives as determined by the Board or
a Committee. If any portion of such bonus is earned, it will be paid when practicable after the Board or a Committee determines it has been earned, subject to you remaining employed with the Company through the payment date. Your annual bonus
opportunity will be subject to review and adjustment based upon the Company’s normal performance review practices. In addition, the Board and/or a Committee may, in its direction, grant you discretionary bonuses from time to time. 

  

					
	Amprius Executive Confirmatory Employment Letter - Confidential	  	
	
	1180 PAGE AVE., FREMONT, CA 94538 * PH: 800.425.8803 * FX: 866.685.7420

 4. Equity Awards. You will be eligible to receive awards of stock options, restricted
stock units or other equity awards pursuant to any plans or arrangements the Company may have in effect from time to time. The Board and/or a Committee will determine in its discretion whether you will be granted any such equity awards and the terms
of any such award in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time. 
 5.
Employee Benefits. As a regular full-time employee of the Company, you will continue to be eligible to participate in Company-sponsored benefits in accordance with the terms of the Company’s policies and benefits plans and receive any
perquisites as may be provided by the Company from time to time. In addition, you will continue to be entitled to paid vacation in accordance with the Company’s paid time off policy, as in effect from time to time. Information regarding
coverage, eligibility, and other information regarding these benefits is set forth in more detailed documents that are available from the Company. With the exception of the Company’s at-will employment
policy, discussed below, the Company may, from time to time, in its sole discretion, modify or eliminate its policies and/or benefits offered to employees. 

6. Severance. If the Company or any successor corporation terminates your employment other than for Cause (as defined below), death or
disability or you terminate your employment with the Company or any successor corporation for Good Reason (as defined below), then, you will be eligible to receive, subject to executing a release of claims in a form approved by the Company as
provided below, the following severance: continuing payments of severance pay at a rate equal to your base salary, as then in effect, for a period of 3 months following the date of such termination, which will be paid in accordance with the
Company’s normal payroll procedures. 
 If your employment is terminated voluntarily by you (other than for Good Reason), for Cause by
the Company or due to your death or disability, then you will only be eligible for severance benefits in accordance with the Company’s established policies, if any, as then in effect. 

The receipt of any severance benefits pursuant to this Agreement will be subject to your signing and not revoking a release of any and all
claims, in a form prescribed by the Company (the “Release”) and provided that such Release becomes effective and irrevocable no later than sixty 60 days following the termination date (such deadline, the “Release
Deadline”). If the Release does not become effective and irrevocable by the Release Deadline, you will forfeit any rights to severance benefits under this Agreement. No severance benefits will be paid or provided until the Release becomes
effective and irrevocable. Upon the Release becoming effective, any payments delayed from the date you terminate employment through the effective date of the Release will be payable in a lump sum without interest as soon as administratively
practicable after the Release becomes effective and irrevocable and all other amounts will be payable in accordance with the payment schedule applicable to each payment or benefit. In the event the termination occurs at a time during the calendar
year where the Release Deadline is in the calendar year following the calendar year in which your termination occurs, then any severance payments under this Agreement that would be considered Deferred Compensation (as defined below) will be paid on,
or in the case of installments, will not commence until, the 60th day after your termination date, or, if later, the Deferred Compensation Delayed Payment Date (as defined below). 

  

					
	Amprius Executive Confirmatory Employment Letter - Confidential	  	Page 2
	
	1180 PAGE AVE., FREMONT, CA 94538 * PH: 800.425.8803 * FX: 866.685.7420

 It is the intent of this Agreement that all payment and benefits hereunder comply with or be
exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and any guidance promulgated thereunder and any applicable state law requirements
(“Section 409A”) so that none of the payments and benefits to be provided under this Agreement will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein
will be interpreted to be exempt or so comply. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury
Regulations. You and the Company agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income
recognition prior to actual payment to you under Section 409A. Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to you, if any, pursuant to this Agreement that, when considered
together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, “Deferred Compensation”) or otherwise would be exempt from Section 409A pursuant to
Treasury Regulation Section 1.409A-1(b)(9) will be paid or otherwise provided until you have a “separation from service” within the meaning of Section 409A. Further, if at the time of your
termination of employment, you are a “specified employee” within the meaning of Section 409A, payment of such Deferred Compensation will be delayed to the extent necessary to avoid the imposition of the additional tax imposed under
Section 409A, which generally means that you will receive payment on the first payroll date that occurs on or after the date that is 6 months and 1 day following your termination of employment, or your death, if earlier (the “Deferred
Compensation Delayed Payment Date”). 
 7. Employee Confidentiality and Invention Assignment. As an employee of the Company,
you will continue to have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property of the Company. To protect the interests of
the Company, you are required to sign and comply with an At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement with the Company (the “Confidential Information
Agreement”), which is incorporated by reference herein. 
 8. Employment Relationship. Employment with the Company will
continue to be for no specific period of time. Your employment with the Company will continue to be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any
contrary representations that may have been made to you are superseded by this Agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the
Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and the Company’s Chief Executive Officer. 

  

					
	Amprius Executive Confirmatory Employment Letter - Confidential	  	Page 3
	
	1180 PAGE AVE., FREMONT, CA 94538 * PH: 800.425.8803 * FX: 866.685.7420

 9. Protected Activity Not Prohibited. Nothing in this Agreement or in any other
agreement between you and the Company, as applicable, will in any way limit or prohibit you from engaging for a lawful purpose in any Protected Activity. For purposes of this Agreement, “Protected Activity” means filing a charge or
complaint, or otherwise communicating, cooperating, or participating with, any state, federal, or other governmental agency, including but not limited to the U.S. Securities and Exchange Commission, the Equal Employment Opportunity Commission, and
the National Labor Relations Board. Notwithstanding any restrictions set forth in this Agreement or in any other agreement between you and the Company, as applicable, you understand that you are not required to obtain authorization from the Company
prior to disclosing information to, or communicating with, such agencies, nor are you obligated to advise the Company as to any such disclosures or communications. In making any such disclosures or communications, you agree to take all reasonable
precautions to prevent any unauthorized use or disclosure of any information that may constitute Company Confidential Information (within the meaning of the Confidential Information Agreement) to any parties other than the relevant government
agencies. You further understand that Protected Activity does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the Company’s written consent will constitute a material
breach of this Agreement. You acknowledge that the Company has provided you with notice in compliance with the Defend Trade Secrets Act of 2016 regarding immunity from liability for limited disclosures of trade secrets. The full text of the notice
is attached in Exhibit A. 
 10. Governing Law; Venue. All questions concerning the construction, validity
and interpretation of this Agreement and the exhibits hereto shall be governed by and construed in accordance with the domestic laws of the State of California, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of California or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of California. Any lawsuit arising out of or in any way related to this Agreement to the Parties’
relationship hereunder shall be brought only in those state or federal courts having jurisdiction over actions arising in Alameda County in the State of California. 

11. Miscellaneous. This Agreement and the Confidential Information Agreement constitute the entire agreement between you and the
Company regarding the subject matters discussed, and they supersede all prior negotiations, representations or agreements between you and the Company. This Agreement may only be modified by a written agreement signed by you and the Company’s
Chief Executive Officer. 
 12. Definitions. 

a. “Board” means the Board of Directors of Amprius Technologies, Inc. 

(Signature page follows) 

  

					
	Amprius Executive Confirmatory Employment Letter - Confidential	  	Page 4
	
	1180 PAGE AVE., FREMONT, CA 94538 * PH: 800.425.8803 * FX: 866.685.7420

 To confirm the current terms and conditions of your employment, please sign and date in the
spaces indicated and return this Agreement to the Company. 
  

			
	Sincerely,
	
	Amprius Technologies, Inc.
		
	By:	 	 /s/ Kang Sun

	Kang Sun
	Chief Executive Officer

 I have read and understood this Agreement and hereby acknowledge, accept and agree to the terms as set
forth herein and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein. 
  

			
	 /s/ Constantin Ionel Stefan

	Constantin Ionel Stefan
		
	Date:	 	September 28, 2022

  

					
	Amprius Executive Confirmatory Employment Letter - Confidential	  	Page 5
	
	1180 PAGE AVE., FREMONT, CA 94538 * PH: 800.425.8803 * FX: 866.685.7420

 Exhibit A 

SECTION 7 OF THE DEFEND TRADE SECRETS ACT OF 2016 

“ . . . An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a
trade secret that—(A) is made—(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation
of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. . . . An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law
may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual—(A) files any document containing the trade secret under seal; and (B) does not disclose the
trade secret, except pursuant to court order.” 

  

					
	Amprius Executive Confirmatory Employment Letter - Confidential	  	Page 6
	
	1180 PAGE AVE., FREMONT, CA 94538 * PH: 800.425.8803 * FX: 866.685.7420EX-10.15

 Exhibit 10.15 

SPECIAL FEES AGREEMENT N°2 

BETWEEN 
 Madeleine Charging B.V., a company
incorporated under Dutch law whose registered office is located at Zuidplein 126, WTC Toren H, 15e, 1077 XV Amsterdam, the Netherlands, registered under number 71768068, duly represented, 

hereinafter referred to as “Madeleine”, 

AND 
 E8 Partenaires, a French
société par actions simplifiée with capital of 8,000 euros, whose registered office is located at 75 avenue des Champs-Elysées, 75008 Paris, registered with the Paris Trade and Companies Register under number 440
366 334 and represented by Mr Bruno Heintz, duly authorised, 
 hereinafter referred to as “E8”, 

Hereinafter also referred to individually as a “Party” and collectively as the “Parties”. 

WHEREAS 
  

	1.	 Madeleine controls the so-called Allego Group, comprising several
holding companies governed by Dutch law and various operating companies. More specifically, Madeleine holds 100% of the capital and voting rights of the holding company Allego Holding, which in turn itself holds, directly and indirectly, around ten
operating subsidiaries located in the Netherlands and in several other countries. 

  

	2.	 On 16 December 2020, the Parties entered into a special fees agreement, as amended on 15 January
2021, 8 April 2021 and 25 April 2021 (the “Original Agreement”), specifying the terms and conditions under which Madeleine shall benefit of the assistance of E8 in the conduct of a Liquidity Event (as this term is defined
in the Original Agreement). A copy of said Original Agreement is attached hereto as an Appendix. 

  

	3.	 In the near future, the Allego Group is planning to complete a SPAC Transaction, following which, Allego will
be wholly owned by Allego N.V., a newly incorporated company governed by Dutch law, whose securities will be admitted to listing on the NYSE (“Allego NV”). 

 

	4.	 In the context of the SPAC Transaction, the Parties decided to come together in order to set out the terms and
conditions under which Allego NV shall benefit of the assistance of E8 in the conduct of future Liquidity Injection processes (as this term is defined hereinafter), particularly in view of optimising the conditions under which these shall occur.

 The Parties have therefore agreed as follows. 

Preliminary Article – Definitions 
 Capitalized terms
and expressions used in this agreement (the “Agreement”) shall have the meaning ascribed to them in this Article. 
 Affiliates:
means for any entity, (i) the entity that, directly or indirectly, Controlls this entity or is Controlled by it, (ii) if the entity is a management company or an investment advisor, any mutual fund (fonds commun de placement) or any
other investment vehicle of which this entity, or any Affiliate of this entity, is the management company or investment advisor or general partner (associé commandité), (iii) if this entity is a mutual fund (fonds commun de
placement) or any other investment vehicle, any person that is the management company or controlling manager (gérant majoritaire) or general partner (associé commandité) of this entity ; it being specified that
the portfolio companies managed by Meridiam S.A.S. and /or its Affiliates are expressly excluded. 

  
 1 

 Allego Group: means Allego NV as well as any entity Controlled by Allego NV (currently or in the
future). 
 Allego Holding: means Allego Holding B.V., a company incorporated under Dutch law whose registered office is located at Westervoortsedijk
73 KB, 6827 AV Arnhem, registered under number 73283752. 
 Control: means, for any given entity, the holding (directly or indirectly) of more than
50% of the share capital and voting rights of such entity, the terms “Control”, “Controlling” and “Controlled” shall be construed accordingly. 

Liquidity Injection: means the issuance of any Security of Allego NV or of any other company Controlled by Meridiam EI S.A.S. provided such company
Controls Allego NV (a “Other Meridiam Company”), by way of share capital increase in cash or by way of contribution in kind as from the date of completion of the SPAC Transaction and until the term of this agreement, it being
specified that in case of contribution in kind, the value of the Securities delivered to Allego NV or to any Other Meridiam Company, if applicable, shall be assessed on the date of the Liquidity Injection considered by reference to their market
value (and, if no agreement is to be reached by the Parties on such value, by Expert opinion). 
 Proceeds: means the subscription price of the
Securities issued in connection with a Liquidity Injection, reduced by any external transaction fees and other related external costs borne by Madeleine and/or Allego NV (including Fees). 

Third Party: means any entity, other than an Allego NV entity and/or one of its Affiliates. 

Securities: means, for an entity, the shares of such entity or any other security giving immediate or deferred access to the share capital of such
entity. 
 SPAC Transaction: means the transaction described in the Business Combination Agreement and Plan of Reorganization dated 28 July
2021, as amended from time to time. 
 ARTICLE 1 - E8 Fees 

The Parties hereby agree that E8 shall receive special fees in the event of a Liquidity Injection (hereinafter, the “Fees”), under the terms
and conditions set forth in Article 2. 
 The Fees are related to the completion of a Liquidity Injection, in the event of which Allego NV would perceive
Proceeds from a Third Party. 
 The amount of the Fees shall correspond to the Applicable Rate (as defined below) multiplied by the amount of the Proceeds
received under a Liquidity Injection. 
 ARTICLE 2 - Applicable Rate 

2.1 The applicable rate for the calculation of the Fees (the “Applicable Rate”) shall be determined by applying following formulas: 

 

	 	•	 	 If VT < 1.2 x VI then the Applicable Rate is zero, 

 

	 	•	 	 If 1.2 x VI <= VT < 2.5 x VI then the Applicable Rate equals to (10% x (VT – 1.2 x VI)) / VT,

  
 2 

	 	•	 	 If 1.8 x VI <= VT < 2.5 x VI then the Applicable Rate equals to (6% x VI + 15% x (VT – 1.8 x VI)) /
VT, 

  

	 	•	 	 If 2.5 x VI <= VT then the Applicable Rate equals to (16.5% x VI + 20% x (VT – 2.5 x VI)) / VT

 where: 
 VI (or initial value of the
Allego NV Securities) equals to €240 million, it being specified that this value shall be adjusted, if applicable, at the time of a relevant Liquidity Injection (except for the amounts received under the SPAC Transaction), for the purpose
of adding any amount received in connection with previous Liquidity Injections. 
 VT (or earned value of the Allego NV Securities) corresponds to the value
of all entities comprising the Allego Group following completion of a relevant Liquidity Injection (post-money). 
 By way of exception, with respect to the
first Liquidity Injection following the completion of the SPAC Transaction, VT will be equal to the greater of (i) the value of the Allego NV Securities at the time of the SPAC Transaction (i.e., on the basis of $10.00 per common share) and
(ii) the value of all of the entities comprising the Allego Group at the time of the completion of such Liquidity Injection (post-money). 
 2.2 In the
event that an initial Liquidity Injection is followed by one or more additional Liquidity Injections, the calculation of the Applicable Rate shall also apply to each such event in accordance with the following formulas, for the application of which:

 VTn = value of the VT variable at the time of the n-th
Liquidity Injection. 
  

	 	•	 	 if VTn <= VTn-1, VTn-1 being the earned value (VT) at the time immediately
preceding the n-th Liquidity Injection, then the Applicable Rate for the n-th Liquidity Injection is zero. 

 

	 	•	 	 if VTn > VTn-1, VTn-1 being the earned value (VT) at the time immediately
preceding the n-th Liquidity Injection, then the Applicable Rate for the n-th Liquidity Injection equals to the rate of the Applicable Rate calculated by applying the
foregoing formulae, using the VTn value. 

 2.3 In any event, the amount of the Fees shall be paid to E8 no later than fifteen days after
completion of the Liquidity Injection by Madeleine. 
 ARTICLE 3 - Rendez-vous clause 

In the event that a Liquidity Injection into any entity of the Allego Group other than Allego NV (an “Alternative Transaction”) is
contemplated, the Parties shall meet and discuss in good faith the adjustments to be made to this Agreement to reflect the Alternative Transaction in the determination of the Fees. 

ARTICLE 4 - Entry into force 
 The Parties agree that this
Agreement is entered into on the date hereof. 
 ARTICLE 5 - Term 

This Agreement shall terminate on the earlier of (i) 30 June 2025 and (ii) the date on which Madeleine would cease to own, directly or indirectly,
any Securities of Allego NV. 
 This Article 5 is without prejudice to the provisions of Articles 1 and 2, so that if one or more Liquidity Injections would
occur, the rights granted to E8 under these Articles shall be fully enforceable, without it being possible to invoke the effects of termination of the contractual relationship. 

  
 3 

 ARTICLE 6 - Acting in good faith 

6.1 If any of the provisions of the Agreement becomes void, unenforceable, invalid or illegal, it shall not call into question the validity, enforceability or
legality of the other provisions of the Agreement. In such event, the Parties shall negotiate in good faith in order to substitute the void, unenforceable, invalid or illegal provision with a lawful provision corresponding to its spirit and purpose
thereof. 
 Likewise, the Parties agree that if, notably for technical reasons, the mechanisms provided for in this Agreement cannot be implemented or
cannot be fully implemented, they shall negotiate in good faith any adjustments that are to be made in compliance with the spirit of the Agreement. 
 6.2
Each Party undertakes to regularize any deed or document necessary to implement the operations provided for in the Agreement and to communicate to the other Party all information necessary for this purpose. 

6.3 The Parties agree that in the event of disagreement concerning the application of the formulas referred to in Article 2 above, they shall appoint by
mutual agreement an independent expert whose mission shall be strictly limited to determining the result of the application of the said formulas (the “Expert”). If no agreement on the appointment of said Expert is reached within
fifteen days following the date on which one of the Parties shall have indicated to the other its wish to proceed with the appointment of an Expert, the latter shall be appointed by the President of the Commercial Court of Paris, referred to by the
most diligent Party. 
 The decision of the Expert shall not be subject to appeal, except in the event of manifest or gross error on his part or violation
of the law and regulations in force. 
 The costs of the expertise shall, unless otherwise agreed by the Parties, be borne equally by the Parties. 

The Expert shall notify the Parties in writing of his findings as soon as possible and where possible, within thirty days of his appointment. 

ARTICLE 7 - Notifications 
 Any notices or communications
under this Agreement shall only be effective if made in writing and sent by registered letter with acknowledgement of receipt (or any equivalent regarding international mail), or by fax (the fax shall be confirmed on the same day by registered
letter with acknowledgement of receipt) to the address and attention of the Party concerned. 
 Such notice shall be deemed received, in the case of faxes,
on the business day following the day of sending, in the case of registered letters with acknowledgement of receipt, on the third business day following the day of sending and in the case of notice delivered by hand, on the day of delivery. 

In the event of a change of address or recipient, the Party concerned shall notify the other Parties in the aforementioned forms. 

ARTICLE 8 - Waiver of Article 1195 of the French Civil Code 

Without prejudice to the other provisions of Article 6 hereof, each Party agrees that the application of the provisions of Article 1195 of the French Civil
Code to its obligations under the Agreement is excluded and acknowledges that it will not be authorized to invoke the provisions of Article 1195 of the French Civil Code. 

  
 4 

 ARTICLE 9 - Successors and assigns 

This Agreement shall apply for the benefit of, and shall bind the Parties and their respective successors, assigns and transferees. The Parties further
acknowledge and agree that Madeleine may freely substitute any Affiliate of its choice (including Allego NV) in its rights and obligations under this Agreement without having to obtain the prior consent of E8. 

ARTICLE 10 - Governing law and disputes 
 The Agreement is
governed by, and shall be construed in accordance with, French law. 
 In the event of a dispute concerning the interpretation or performance of the
Agreement, the Parties shall endeavour to resolve their dispute amicably, within a period not exceeding one month. 
 At the end of such period, the dispute
shall be exclusively subject to the jurisdiction of the courts within the jurisdiction of the Paris Court of Appeal. 

  
 5 

 In Paris, 
 On
25 February 2022, 
 In four original copies, each Party acknowledging to have received its own copy and one copy being intended for registration, the
Parties having agreed to register this deed. 
 Madeleine 
  

	
	 /s/ Julien Touati

By: Julien Touati

 E8 
  

	
	 /s/ Bruno Heintz

By: Bruno Heintz

  
 6 

 AMENDMENT N°1 TO THE SPECIAL FEES AGREEMENT N°2 

BETWEEN: 
 Madeleine Charging B.V., a company
incorporated under Dutch law whose registered office is located at Zuidplein 126, WTC Toren H, 15e, 1077 XV Amsterdam, the Netherlands, registered under number 71768068, duly represented, 

hereinafter referred to as “Madeleine”, 

AND 
 E8 Partenaires, a French
société par actions simplifiée with capital of 8,000 euros, whose registered office is located at 75 avenue des Champs-Elysées, 75008 Paris, registered with the Paris Trade and Companies Register under number 440
366 334 and represented by Mr Bruno Heintz, duly represented, 
 hereinafter referred to as “E8”, 

Madeleine and E8 are hereinafter collectively referred to as the “Parties” and, individually, as a “Party”. 

WHEREAS: 
  

	(A)	 On 25 February 2022, the Parties entered into a “Special Fees Agreement N°2”, in relation to
the assistance of E8 in the preparation and conduct of future processes in connection with Liquidity Injections (as such term is defined in said agreement), with a view to notably optimize the conditions under which these would occur (the
“Agreement”). 

  

	(B)	 The Parties wish to further specify certain items relating to the determination of the Applicable Rate (as such
term is defined in said agreement). 

  

	(C)	 Therefore, the Parties have therefore decided to enter into this amendment to the Agreement (the
“Amendment”). 

 IT HAS BEEN AGREED AS FOLLOWS: 

1. DEFINITIONS AND INTERPRETATION 
 Capitalized terms not
otherwise defined herein shall have the meaning ascribed to them in the Agreement. 
 2. AMENDMENT TO THE AGREEMENT  

Article 2.2 of the Agreement is amended as follows: 
 “In
the event that a first Liquidity Injection is followed by one or more other Liquidity Injections, the computation of the Applicable Rate shall also apply to each such event with the VT value taken at the time of the event considered by the relevant
Liquidity Injection.” 
 3. MISCELLANEOUS 
 The
Amendment shall come into force as of its signature by all Parties. The other provisions of the Agreement remain unchanged and in full force. 

  
 1 

 4. GOVERNING LAW AND COMPETENT COURTS 

This Amendment and any contractual or non-contractual obligation arising out of or relating to it shall be exclusively
governed by and construed in accordance with French law. 
 All disputes arising out of or relating to this Amendment (including, but not limited to, those
relating to the existence, validity, application, termination and interpretation of this Amendment and any non-contractual obligations arising out of or relating to it) shall be subject to the exclusive
jurisdiction of the Commercial Court of Paris. 

  
 2 

	
	In Paris, on 10 March 2022,
	
	 /s/ Julien Touati

	Madeline Charging B.V.
	By: Julien Touati, duly authorised

  
 3 

	
	 /s/ Bruno Heintz

	E8 Partenaires
	By: Bruno Heintz, duly authorised

  
 4 

 
NOVATION AGREEMENT 

BETWEEN THE UNDERSIGNED: 
  

	(1)	 Madeleine Charging B.V., a Dutch besloten vennootschap met beperkte aansprakelijkheid, having its
registered office at Zuidplein 126, WTC Toren H, 15e, 1077 XV Amsterdam, the Netherlands, registered under number 71768068, duly represented for the purposes hereof; 

(hereafter referred to as the “Transferor”) 
  

	(2)	 Allego N.V., a Dutch naamloze vennootschap, having its registered office at Westervoortsedijk 73
KB, 6827 AV Arnhem, the Netherlands, registered under number 82985537, duly represented for the purposes hereof; 

(hereafter referred to as the “Transferee”) 

AND 
  

	(3)	 E8 Partenaires, a French société par actions simplifiée, having its
registered office at 75 avenue des Champs Elysées, 75008 Paris, registered with the Paris Trade and Companies Register under number 440 366 334, duly represented for the purposes hereof; 

(hereafter referred to as the “Remaining Party”) 

The above parties listed in (1) to (3) are hereafter collectively referred to as the “Parties” and individually as a
“Party”. 
 WHEREAS: 
  

	(A)	 The Transferor and the Remaining Party are parties to a convention d’honoraires
exceptionnels dated as of 25 February 2022, as amended on 10 March 2022 (the “Special Fees Agreement No. 2”) 

 

	(B)	 With effect from the Novation Time on the Novation Date, the Transferor wishes to transfer its rights and
obligations under the Special Fee Agreement No. 2 to the Transferee. The Remaining Party agrees to such transfer by way of novation of the Special Fee Agreement No. 2 in accordance with the terms set out in this Agreement.

  

	(C)	 With effect from the Novation Time on the Novation Date, the Transferee agrees to such transfer by way of a
novation of the Special Fee Agreement No. 2 in accordance with the terms set out in this Agreement. 

 THE PARTIES TO THIS AGREEMENT AGREE AS FOLLOWS: 

 

	1	 Definitions and Interpretation 

 

	1.1	 Capitalized terms and expressions shall, save where defined in Clause 1.5 below, bear the meanings set out in
the Special Fee Agreement No. 2 . 

  

	1.2	 The headings in this Agreement are for convenience only and shall not affect the interpretation hereof.

  

	1.3	 References to recitals and clauses are to the recitals and clauses of this Agreement, unless specified
otherwise. 

  

	1.4	 References to any agreement or instrument shall mean a reference to that agreement or instrument as amended,
supplemented, restated and/or modified from time to time. 

  

	1.5	 In this Agreement, the following words and expressions shall, unless the context otherwise requires, bear the
following meanings: 

 Agreement means this Novation Agreement; 

Novation Date means 5 May 2022; 

Novation Time means 00:00 CET. 
  

	2	 Novation 

 

	2.1	 In consideration of the mutual undertakings of the Parties in this Agreement, and with effect as of the
Novation Time on the Novation Date, the Parties agree as follows: 

  

	 	(i)	 the Special Fee Agreement No. 2 is hereby transferred by way of novation in accordance with articles 1329
and seq. of the French Civil Code, such that the Transferee assumes all of the Transferor’s rights, claims, liabilities and obligations under the Special Fee Agreement No. 2 , whenever created or incurred to the same extent as if
the Transferee had been an original party thereto and both the Remaining Party and the Transferee shall perform their rights, claims, liabilities and obligations under the Special Fee Agreement No. 2 and be bound by its terms as if the
Transferee had at all times been a party to the Special Fee Agreement No. 2 in place of the Transferor; 

  

	 	(ii)	 As a result of such transfer by way of novation, the Transferor and the Remaining Party are each released and
discharged from further obligations to each other, and their respective rights against each other are hereby cancelled, in respect of the Special Fee Agreement No. 2. 

 

	2.2	 The Parties agree that (i) the Transferee may, at its entire discretion, decide to delegate any of its
subsidiaries (the “Délégué”) to the Remaining Party for the payment of all sums due under the Special Fee Agreement No. 2 to the Remaining Party, under the meaning of Articles 1336 to 1340 of the
French Civil Code, and that, as the case may be, (ii) this delegation of payment shall be “perfect” (delegation parfaite) under the meaning of Article 1337, first Paragraph, of the French Civil Code, which means that the
commitment taken by the Délégué vis-a-vis the Transferee shall substitute in all respects to the obligation of payment subscribed by the
Transferee vis-a-vis the Remaining Party. The terms and conditions of such delegation are attached hereto. 

 For the avoidance of doubt, the Remaining Party hereby agrees the
Délégué as substituted debtor, and acknowledges that, if such delegation is decided by the Transferee and a copy of the executed delegation notified to the Remaining Party, (i) Transferee’s debt shall be purely
and simply substituted by the Délégué’s debt, as provided by Article 1337, first Paragraph of the French Civil Code, and (ii) the Remaining Party shall therefore have no remedy against the Transferee. However,
the Transferee hereby agrees, in accordance with Article 1337 of the French Civil Code, to guarantee the Remaining Party against the insolvency of the Délégué; it being however specified that any recourse by the Remaining
Party against the Transferee may only be initiated after a judicial determination of the Délégué’s insolvency or bankruptcy. 
  

	3	 Representations and Warranties 

Each Party represents and warrants to the others that as at the date hereof (with such representations and warranties being deemed to be
repeated at the Novation Time on the Novation Date): 
  

	 	(i)	 it is duly organized and validly existing under the laws of the jurisdiction of its incorporation, and has the
corporate power and authority to execute, deliver and perform the terms and provisions of this Agreement; 

  

	 	(ii)	 the performance of this Agreement does not and will not violate or conflict with its charter or by-laws, any law or order of any court or other agency of government applicable to it, or any agreement to which it is a party or by which it or any of its property is bound; 

 

	 	(iii)	 this Agreement constitutes its legally valid and binding obligation, is enforceable against it in accordance
with its terms and the enforceability of this Agreement is not limited by the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights or by general principles of equity;

  

	 	(iv)	 no actual or potential default, event of default or material reason (or other 1ike event or circumstance
however described in the Special Fee Agreement No. 2) with respect to it has occurred and is continuing immediately prior to it entering into this Agreement and no such event or circumstance would occur as a result of its entering into or
performing its obligations under this Agreement. 

  

	4	 Further Assurances 

The Parties shall perform, execute and deliver such further acts and documents as may be required by law or reasonably requested by each other
to implement the purposes of this Agreement. 
  

	5	 Invoicing &VAT 

Notwithstanding any other provision of this Agreement, the Parties agree that for VAT and invoicing purposes, deliveries shall be invoiced
between the Remaining Party and the Transferee or between the Remaining Party and the Délégué that the Transferee would have delegated for the payment of any sums due in accordance with Clause 2.2 above. 

For the avoidance of doubt, invoicing also includes the correction or amendment of invoices and the issuing of credit notes. 

 

	6	 Costs 

The Parties shall bear their own costs, charges and expenses (including, without limitation, legal expenses) in relation to the preparation,
negotiation and execution of this Agreement. 

	7	 Amendments 

No amendment, modification or waiver in respect of this Agreement, including this clause, will be effective unless in writing and executed by
each of the Parties. 
  

	8	 Severability 

If any of the provisions of this Agreement is or becomes ineffective, the effectiveness of the other provisions shall not be affected. In such
case, the Parties undertake to replace the ineffective provision by an effective provision which achieves an economic result as similar as possible to that of the provision so replaced. This shall apply mutatis mutandis to any lacuna
in this Agreement. 
  

	9	 Law and Jurisdiction 

This Agreement, and any dispute or claim arising out of or in connection with this Agreement or it subject matter or formation, including any non-contractual disputes or claims, will be exclusively governed by and construed in accordance with French law. 

All disputes relating to this agreement shall be resolved exclusively by the Tribunal de Commerce of Paris. 

 

	10	 Electronic Signature 

 

	10.1	 The Parties hereto hereby agree that, as a matter of evidence agreement (convention de preuve), this
Agreement is signed electronically in accordance with the European and French regulations in force, in particular Regulation (EU) No. 910/2014 of the European Parliament and of the Council dated 23 July 2014 and articles 1367 et
seq. of the French Code civil. For this purpose, the Parties hereto agree to use the online platform DocuSign (www.docusign.com). Each of the Parties hereto decides (i) that the electronic signature which it attaches to this
Agreement has the same legal value as its handwritten signature and (ii) that the technical means implemented in the context of this signature confer a definite date (date certaine) to this Agreement. 

 

	10.2	 Each of the Parties hereto acknowledges and accepts that the signature process used to electronically sign this
Agreement enables each of them to have a copy of this Agreement on a durable medium or to have access to it, in accordance with Article 1375 paragraph 4 of the French Code civil. 

Made in Paris on 5 May 2022. 
  

			
	The Transferor	  	The Transferee
		
	 /s/ Julien Touati
	  	 /s/ Mathieu Bonnet

		
	Madeleine Charging B.V.	  	Allego N.V.
	By: Julien Touati	  	By: Mathieu Bonnet
	Title: Authorized signatory	  	Title: Authorized signatory

	
	The Remaining Party
	
	 /s/ Bruno Heintz

	
	E8 Partenaires
	By: Bruno Heintz
	Title: Authorized signatory

 Schedule 

Draft delegation of payment 

BETWEEN THE UNDERSIGNED: 
 Allego N.V., a Dutch
naamloze vennootschap, having its registered office at Westervoortsedijk 73 KB, 6827 AV Arnhem, the Netherlands, registered under number 82985537, duly represented for the purposes hereof; (“Allego” or the
“Délégant”) 
 and 

                 (the “Délégué’’),

 hereinafter individually referred to as the “Party” and together as the “Parties”. 

WHEREAS: 
  

	(A)	 Madeleine Charging B.V. and E8-Partenaires signed on 25 February 2022,
as amended on 10 March 2022 a convention d’honoraires exceptionnels n°2 subject to French law (the “Convention”), a copy of which is attached as Schedule 1; 

 

	(B)	 By an agreement entered into between Madeleine Charging B.V. (as transferor), Allego N.V. (as transferee) and
E8 Partenaires SAS (as remaining party), dated on 5 May 2022, the Convention was assigned by Madeleine Charging B.V. to Allego N.V. (the “Novation Agreement”), a copy of which is attached as Schedule 2.

  

	(C)	 Pursuant to Clause 2.2 of the Novation Agreement, the parties thereto allowed Allego N.V. to delegate any of
its subsidiary to E8 Partenaires (the “Délégataire”) for the payment of the services provided for by the Convention (the “Créance du Délégataire”), it being specified that the
Délégataire consented to this in advance without reservation. 

  

	(D)	 Allego N.V. wishes to exercise this option and, as a result, Allego N.V. and
                 intends to set forth the terms and conditions pursuant to which this option will be implemented (the “Delegation”).

  

	(E)	 The Parties agree that the delegation organized by the Delegation is “perfect”
(délégation parfait) within the meaning Article 1336 of the French Civil Code, which means that the commitment made by the Délégué towards the Délégataire releases and replaces
the obligation of the Délégant towards the Délégataire. 

 THE PARTIES TO THIS AGREEMENT AGREE AS FOLLOWS: 

Article 1 
 The Délégant
delegates the Délégué, for the benefit of the Délégataire and with novatory effect, in the payment of all sums in principal, interest, indemnities, costs and incidental expenses for which he is or
will be liable to the Délégataire in respect of the Créance du Délégataire. 
 This delegation entails
novation by a change of creditor of the Creance du Délégataire and, consequently, the extinction of all the actions attached thereto. 

It is understood and agreed that, in accordance with Article 1339 of the French Civil Code, if the Délégataire releases the
Délégant from its debt, the Délégué shall ipso jure be released from its debt vis-à-vis the
Délégataire, up to the amount of its remaining commitment to the Délégataire. The Délégant undertakes to inform the Délégué of such release without
delay. 
 Article 2 
 The
Délégué declares that it consents to the Delegation with novatory effect and, consequently, acknowledges that it is directly liable to the Délégataire (as sole debtor) for the payment in full of the
sums which are or will be due to it by the Délégant in accordance with the terms of the Convention. 
 Under no circumstances may the
Délégué raise against the Délégataire any exceptions arising from its contractual nexus with the Délégant. 

The rights and/or obligations under this Delegation may not be assigned or transferred, in all or in part, by a Party to any third party. 

Article 3 
 The Délégant
undertakes to inform the Délégataire without delay of the entry into of this Delegation. 
 The Délégué
undertakes to inform the Délégant without delay of the execution, in part or in full, of the Delegation. 
 Article 4

 The Delegation comes into force as of the date on which each Party executes it. It shall terminate on the date of its full execution, including in
the event of extension or termination of the Convention by the Délégant. 

 Article 5 

This Agreement, and any dispute or claim arising out of or in connection with this Agreement or it subject matter or formation, including any non-contractual disputes or claims, will be exclusively governed by and construed in accordance with French law. 
 All
disputes relating to this agreement shall be resolved exclusively by the Tribunal de Commerce of Paris. 
 Made in
                 on                 , 

 

			
	Délégué	  	Délégant
		
	  
 By:
	  	  
 Allego N.V.

	Title:	  	By:                 
		  	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]